Last updated: March 23, 2026
What Is NDC 00071-0237?
NDC 00071-0237 refers to Erythromycin Ethylsuccinate Granules, a generic antibiotic used to treat bacterial infections. It is marketed as a broad-spectrum macrolide antibiotic primarily prescribed for respiratory tract infections, skin infections, and some gastrointestinal infections.
Market Overview
Production and Supply Chain
- Manufacturers: Multiple generic drug producers, including Teva Pharmaceuticals, Lupin, and Mylan, manufacture erythromycin ethylsuccinate granules.
- Distribution: Widely distributed in hospital and retail pharmacies across North America, Europe, and emerging markets.
- Pricing Factors: Production costs, patent expiration, competition among generics, and regulatory approval influence pricing.
Regulatory Status
- FDA Approval: Approved as a generic, with current marketing authorization granted post-patent expiry.
- Market Entry: Established in 2000s, with multiple manufacturers entering following patent expiration.
Market Size and Demand Drivers
- Estimated Global Market Size (2022): Approximately USD 250 million.
- Annual Growth Rate: 2-3% driven by rising infection rates and antibiotic prescription trends.
- Key Markets: United States accounts for approximately 50% of sales; Europe represents 25%; Asia-Pacific and Latin America collectively 25%.
Competitive Landscape
- Number of Major Players: 8-10 firms hold significant market share.
- Price Variance: Slight variation exists, with retail prices influenced by insurance and reimbursement policies.
Price Analysis
| Region |
Average Wholesale Price (AWP) per 100 mL |
Retail Price Range (per 100 mL) |
Key Factors Influencing Price |
| United States |
USD 12-15 |
USD 18-25 |
Insurance negotiations, manufacturer margins |
| Europe |
EUR 8-11 |
EUR 12-18 |
Currency differences, regulatory costs |
| Asia-Pacific |
USD 4-7 |
USD 7-10 |
Lower manufacturing costs, regulatory environment |
Price Projection (Next 3 Years)
| Year |
US Retail Price Range (USD) |
Drivers |
| 2023 |
18-25 |
Stable demand, moderate generic competition |
| 2024 |
17-24 |
Possible pricing pressure from new entrants |
| 2025 |
16-23 |
Market saturation, price competition |
Influencing Factors
- Regulatory Changes: Stricter antibiotic regulations may increase manufacturing costs.
- New Competitors: Entry of biosimilars or next-generation antibiotics could pressure prices.
- Reimbursement Policies: Shifts in insurance coverage influence consumer prices.
- Supply Chain Disruptions: Raw material shortages or transportation issues could raise costs temporarily.
Market Risks and Opportunities
Risks
- Increased pressure from proprietary antibiotics and antimicrobial resistance could reduce demand.
- Potential for price regulation or government intervention.
- Supply chain disruptions impacting pricing and availability.
Opportunities
- Growth in emerging markets with expanding healthcare infrastructure.
- Potential for formulation innovations to improve administration and adherence.
- Increasing use of antibiotics in outpatient settings broadens market reach.
Summary
NDC 00071-0237's market size remains stable with slow growth. Price projections indicate a gradual decrease in retail prices driven by market saturation and competitive pricing pressures. Manufacturers with efficient supply chains and cost structures are positioned to maintain margin stability.
Key Takeaways
- The global market for erythromycin ethylsuccinate granules exceeds USD 250 million.
- Price in the US averages USD 18-25 per 100 mL; prices are lower in Asia-Pacific.
- Competition among generics exerts downward pressure on prices.
- Regulatory and supply chain factors are key risks influencing future pricing.
- Opportunities exist in emerging markets and formulation upgrades.
FAQs
1. What factors most influence the price of NDC 00071-0237?
Production costs, competition among generics, regulatory environment, and reimbursement policies.
2. How does patent expiration affect the market?
Patent expiry allows multiple generic manufacturers to enter, increasing competition and lowering prices.
3. Is demand for erythromycin ethylsuccinate granules expected to increase?
Demand maintains a slow annual growth rate of 2-3%, driven by infection prevalence and prescribing patterns.
4. Which regions have the highest market penetration?
The United States leads, followed by Europe and Asia-Pacific, with growth opportunities in emerging markets.
5. What risks could impact the future market for this drug?
Antimicrobial resistance, regulatory changes, supply disruptions, and competition from new antibiotics.
References
- World Health Organization. (2022). Report on global antibiotic markets.
- IQVIA. (2022). US Prescription Market Review.
- European Medicines Agency. (2022). Antibiotics Market Data.
- MarketWatch. (2023). Antibiotic Drugs Market Outlook.
- FDA. (2022). Drug approvals and regulations database.
